515846-33-0

Basic information

• Product Name: (R)-[1-(2-{4-[3-(2,3-dichloro-4-triisopropylsilanyloxy-phenyl)-3-oxo-prop-1-ynyl]-piperidin-1-yl}-2-oxo-ethylcarbamoyl)-3-methyl-butyl]-carbamic acid tert-butyl ester
• Synonyms: (R)-[1-(2-{4-[3-(2,3-dichloro-4-triisopropylsilanyloxy-phenyl)-3-oxo-prop-1-ynyl]-piperidin-1-yl}-2-oxo-ethylcarbamoyl)-3-methyl-butyl]-carbamic acid tert-butyl ester
• CAS NO: 515846-33-0
• Molecular Weight: 724.841
• Mol File: 515846-33-0.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: (R)-[1-(2-{4-[3-(2,3-dichloro-4-triisopropylsilanyloxy-phenyl)-3-oxo-prop-1-ynyl]-piperidin-1-yl}-2-oxo-ethylcarbamoyl)-3-methyl-butyl]-carbamic acid tert-butyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-[1-(2-{4-[3-(2,3-dichloro-4-triisopropylsilanyloxy-phenyl)-3-oxo-prop-1-ynyl]-piperidin-1-yl}-2-oxo-ethylcarbamoyl)-3-methyl-butyl]-carbamic acid tert-butyl ester(515846-33-0)
• EPA Substance Registry System: (R)-[1-(2-{4-[3-(2,3-dichloro-4-triisopropylsilanyloxy-phenyl)-3-oxo-prop-1-ynyl]-piperidin-1-yl}-2-oxo-ethylcarbamoyl)-3-methyl-butyl]-carbamic acid tert-butyl ester(515846-33-0)

Safety Data

• Hazardous Substances Data: 515846-33-0(Hazardous Substances Data)

Upstream product

• 732242-82-9 2-amino-1-(4-ethynyl-piperidin-1-yl)-ethanone 
• 738577-08-7 4-ethynylpiperidine 
• 550378-30-8 4-ethynylpiperidine hydrochloride salt 
• 550378-32-0 2-amino-1-(4-ethynyl-piperidin-1-yl)-ethanone; hydrochloride 
• 515846-30-7 2,3-dichloro-4-triisopropylsilanyloxy-benzoic acid 
• 550378-31-9 [2-(4-ethynyl-piperidin-1-yl)-2-oxo-ethyl]-carbamic acid tert-butyl ester 
• 515846-27-2 (4-bromo-2,3-dichloro-phenoxy)-triisopropyl-silane 
• 287192-97-6 4-ethynyl-piperidine-1-carboxylic acid tert-butyl ester 
• 16937-99-8 N-Boc-D-Leu 
• 576-24-9 2,3-dichlorophenol 
• 13154-24-0 triisopropylsilyl chloride 
• 515846-31-8 2,3-dichloro-4-triisopropylsilanyloxy-benzoyl chloride 
• 515846-24-9 (R)-{1-[2-(4-ethynyl-piperidin-1-yl)-2-oxo-ethylcarbamoyl]-3-methyl-butyl}carbamic acid tert-butyl ester 
• 1940-44-9 4-bromo-2,3-dichlorophenol 

Downstream Products

• 515846-36-3 (R)-[1-(2-{4-[5-(2,3-dichloro-4-hydroxy-phenyl)-2-methyl-2H-pyrazol-3-yl]-piperidin-1-yl}-2-oxo-ethylcarbamoyl)-3-methyl-butyl]-carbamic acid tert-butyl ester 
• 515846-39-6 (R)-5-[4-(5-{1-[2-(2-tert-butoxycarbonylamino-4-methyl-pentanoylamino)acetyl]-piperidin-4-yl}-1-methyl-1H-pyrazol-3-yl)-2,3-dichloro-phenoxymethyl]furan-2-carboxylic acid methyl ester 
• 515846-48-7 (R)-3-[4-(5-{1-[2-(2-tert-butoxycarbonylamino-4-methyl-pentanoylamino)acetyl]-piperidin-4-yl}-1-methyl-1H-pyrazol-3-yl)-2,3-dichloro-phenoxymethyl]benzoic acid 
• 515846-59-0 (R)-4-[4-(5-{1-[2-(2-tert-butoxycarbonylamino-4-methyl-pentanoylamino)acetyl]-piperidin-4-yl}-1-methyl-1H-pyrazol-3-yl)-2,3-dichloro-phenoxymethyl]benzoic acid 
• 515846-42-1 (R)-5-[4-(5-{1-[2-(2-tert-butoxycarbonylamino-4-methyl-pentanoylamino)acetyl]-piperidin-4-yl}-1-methyl-1H-pyrazol-3-yl)-2,3-dichloro-phenoxymethyl]furan-2-carboxylic acid 
• 515846-55-6 (R)-4-[4-(5-{1-[2-(2-tert-butoxycarbonylamino-4-methyl-pentanoylamino)acetyl]-piperidin-4-yl}-1-methyl-1H-pyrazol-3-yl)-2,3-dichloro-phenoxymethyl]benzoic acid methyl ester 
• 515846-46-5 (R)-3-[4-(5-{1-[2-(2-tert-butoxycarbonylamino-4-methyl-pentanoylamino)acetyl]-piperidin-4-yl}-1-methyl-1H-pyrazol-3-yl)-2,3-dichloro-phenoxymethyl]benzoic acid allyl ester 

Relevant articles and documents

TARGETED BIFUNCTIONAL DEGRADERS

The present invention provides, in one aspect, bifunctional compounds that can be used to promote or enhance degradation of certain circulating proteins. In another aspect, the present invention provides bifunctional compounds that can be used to promote or enhance degradation of certain autoantibodies. In certain embodiments, treatment or management of a disease and/or disorder requires degradation, removal, or reduction in concentration of the circulating protein or the autoantibody in the subject. Thus, in certain embodiments, administration of a compound of the invention to the subject removes or reduces the circulation concentration of the circulating protein or the autoantibody, thus treating, ameliorating, or preventing the disease and/or disorder. In certain embodiments, the circulating protein is TNF.

Integrating fragment assembly and biophysical methods in the chemical advancement of small-molecule antagonists of IL-2: An approach for inhibiting protein-protein interactions

Fragment assembly has shown promise for discovering small-molecule antagonists for difficult targets, including protein-protein interactions. Here, we describe a process for identifying a 60 nM inhibitor of the interleukin-2 (IL-2)/IL-2 receptor (IL-2Rα)